Lee P H, Kim J W, Bang O Y, Ahn Y H, Joo I S, Huh K
Department of Neurology, Ajou University College of Medicine, Suwon, South Korea.
Clin Pharmacol Ther. 2008 May;83(5):723-30. doi: 10.1038/sj.clpt.6100386. Epub 2007 Sep 26.
We evaluated the feasibility and safety of therapy with mesenchymal stem cells (MSCs) through consecutively intra-arterial and three repeated intravenous injections and compared the long-term prognosis between MSC-treated (n=11) and control multiple system atrophy (MSA) patients (n=18). The MSC-treated patients showed significantly greater improvement on the unified MSA rating scale (UMSARS) than the control patients at all visits throughout the 12-month study period. Orthostasis in UMSARS I items and cerebellar dysfunction-related items of UMSARS II items were significantly different in favor of MSC treatment compared to controls. Serial positron emission tomography scan in the MSC-treated group showed that increased fluorodeoxyglucose uptake from baseline was noted in cerebellum and frontal white matters. No serious adverse effects related to MSC therapy occurred. This study demonstrated that MSC therapy in patients with MSA was safe and delayed the progression of neurological deficits with achievement of functional improvement in the follow-up period.
我们通过连续动脉内注射和三次重复静脉注射评估了间充质干细胞（MSC）治疗的可行性和安全性，并比较了接受MSC治疗的患者（n = 11）和对照多系统萎缩（MSA）患者（n = 18）的长期预后。在整个12个月的研究期间，接受MSC治疗的患者在统一MSA评定量表（UMSARS）上的改善明显大于对照患者。与对照组相比，UMSARS I项中的直立性低血压和UMSARS II项中与小脑功能障碍相关的项目在接受MSC治疗方面有显著差异。接受MSC治疗组的系列正电子发射断层扫描显示，小脑和额叶白质中氟脱氧葡萄糖摄取量较基线增加。未发生与MSC治疗相关的严重不良反应。本研究表明，MSA患者的MSC治疗是安全的，并且在随访期间延迟了神经功能缺损的进展并实现了功能改善。
